Log in

Ironwood Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IRWD)

$8.88
+0.14 (+1.60 %)
(As of 10/22/2019 08:05 AM ET)
Today's Range
$8.72
Now: $8.88
$8.93
50-Day Range
$8.15
MA: $8.99
$9.76
52-Week Range
$7.91
Now: $8.88
$17.11
Volume639,876 shs
Average Volume1.35 million shs
Market Capitalization$1.39 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.79
Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IRWD
CUSIP46333X10
Phone617-621-7722

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$346.64 million
Book Value($1.27) per share

Profitability

Net Income$-282,370,000.00

Miscellaneous

Employees515
Market Cap$1.39 billion
Next Earnings Date10/31/2019 (Confirmed)
OptionableOptionable

Receive IRWD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.


Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its earnings results on Tuesday, July, 30th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.07) by $0.15. The biotechnology company earned $102.22 million during the quarter, compared to analyst estimates of $89.28 million. Ironwood Pharmaceuticals's revenue was up 26.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.22) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

When is Ironwood Pharmaceuticals' next earnings date?

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, October 31st 2019. View Earnings Estimates for Ironwood Pharmaceuticals.

How can I listen to Ironwood Pharmaceuticals' earnings call?

Ironwood Pharmaceuticals will be holding an earnings conference call on Thursday, October 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?

Ironwood Pharmaceuticals updated its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $370-390 million, compared to the consensus revenue estimate of $374.63 million.

What price target have analysts set for IRWD?

11 equities research analysts have issued twelve-month target prices for Ironwood Pharmaceuticals' stock. Their forecasts range from $12.00 to $20.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $15.05 in the next year. This suggests a possible upside of 69.5% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.

What is the consensus analysts' recommendation for Ironwood Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.

Has Ironwood Pharmaceuticals been receiving favorable news coverage?

News coverage about IRWD stock has been trending very negative this week, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Ironwood Pharmaceuticals earned a news impact score of -3.9 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the stock's share price in the next few days. View News Stories for Ironwood Pharmaceuticals.

Who are some of Ironwood Pharmaceuticals' key competitors?

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Allergan (AGN) and Continental Resources (CLR).

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the folowing people:
  • Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 55)
  • Mr. Thomas A. McCourt, Pres (Age 62)
  • Ms. Gina R. Consylman CPA, CFO, Sr. VP & Treasurer (Age 46)
  • Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 49)
  • Dr. Christopher I. Wright, Chief Devel. Officer & Sr. VP of Global Devel.

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (0.81%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

Which major investors are buying Ironwood Pharmaceuticals stock?

IRWD stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. View Insider Buying and Selling for Ironwood Pharmaceuticals.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $8.88.

How big of a company is Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals has a market capitalization of $1.39 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. Ironwood Pharmaceuticals employs 515 workers across the globe.View Additional Information About Ironwood Pharmaceuticals.

What is Ironwood Pharmaceuticals' official website?

The official website for Ironwood Pharmaceuticals is http://www.ironwoodpharma.com/.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]


MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  440 (Vote Outperform)
Underperform Votes:  536 (Vote Underperform)
Total Votes:  976
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel